PD‑1/PD‑L1 immune checkpoint in bone and soft tissue tumors (Review)
- Authors:
- Kazuhiko Hashimoto
- Shunji Nishimura
- Koji Goto
-
Affiliations: Department of Orthopedic Surgery, Kindai University Hospital, Osaka‑Sayama, Osaka 589‑8511, Japan - Published online on: January 29, 2025 https://doi.org/10.3892/mco.2025.2826
- Article Number: 31
-
Copyright: © Hashimoto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Lin X, Kang K, Chen P, Zheng Z, Li G, Xiong W, Yi M and Xiang B: Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol Cancer. 23(108)2024.PubMed/NCBI View Article : Google Scholar | |
|
Pipitone RM, Lupo G, Zito R, Javed A, Petta S, Pennisi G and Grimaudo S: The PD-1/PD-L1 axis in the biology of MASLD. Int J Mol Sci. 25(3671)2024.PubMed/NCBI View Article : Google Scholar | |
|
Liu J, Chen Z, Li Y, Zhao W, Wu J and Zhang Z: PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 12(731798)2021.PubMed/NCBI View Article : Google Scholar | |
|
Yi M, Li T, Niu M, Mei Q, Zhao B, Chu Q, Dai Z and Wu K: Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 22(187)2023.PubMed/NCBI View Article : Google Scholar | |
|
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L and Wang S: The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 13(964442)2022.PubMed/NCBI View Article : Google Scholar | |
|
Gao W, Liu S, Wu Y, Wei W, Yang Q, Li W, Chen H, Luo A, Wang Y and Liu Z: Enhancer demethylation-regulated gene score identified molecular subtypes, inspiring immunotherapy or CDK4/6 inhibitor therapy in oesophageal squamous cell carcinoma. EBioMedicine. 105(105177)2024.PubMed/NCBI View Article : Google Scholar | |
|
Wood GE, Meyer C, Petitprez F and D'Angelo SP: Immunotherapy in sarcoma: Current data and promising strategies. Am Soc Clin Oncol Educ Book. 44(e432234)2024.PubMed/NCBI View Article : Google Scholar | |
|
Martin-Broto J, Hindi N and Moura DS: Combination treatment with PD1/PDL-1 inhibitors for sarcomas: State of the art, next questions. Curr Opin Oncol. 36:269–275. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Anastasiou M, Kyriazoglou A, Kotsantis I, Economopoulou P, Kyrkasiadou M, Giannopoulou A, Kosmidou A, Smerdi D, Moutafi M, Gavrielatou N and Psyrri A: Immune checkpoint inhibitors in sarcomas: A systematic review. Immunooncol Technol. 20(100407)2023.PubMed/NCBI View Article : Google Scholar | |
|
Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med. 8:793–800. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Hashimoto K, Nishimura S and Akagi M: Characterization of PD-1/PD-L1 immune checkpoint expression in osteosarcoma. Diagnostics (Basel). 10(528)2020.PubMed/NCBI View Article : Google Scholar | |
|
Paydas S, Bagir EK, Deveci MA and Gonluses G: Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas. Med Oncol. 33(93)2016.PubMed/NCBI View Article : Google Scholar | |
|
Torabi A, Amaya CN, Wians FH Jr and Bryan BA: PD-1 and PD-L1 expression in bone and soft tissue sarcomas. Pathology. 49:506–513. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Pérez L, Wehweck FS, Lindner L, Issels R, et al: A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas. Cancer Immunol Immunother. 69:1353–1362. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Miyake M, Oda Y, Nishimura N, Morizawa Y, Ohnishi S, Hatakeyama K, Fujii T, Hori S, Gotoh D, Nakai Y, et al: Integrative assessment of clinicopathological parameters and the expression of PD L1, PD L2 and PD 1 in tumor cells of retroperitoneal sarcoma. Oncol Lett. 20(190)2020.PubMed/NCBI View Article : Google Scholar | |
|
Boxberg M, Steiger K, Lenze U, Rechl H, von Eisenhart-Rothe R, Wörtler K, Weichert W, Langer R and Specht K: PD-L1 and PD-1 and characterization of tumor-infiltrating lymphocytes in high grade sarcomas of soft tissue–prognostic implications and rationale for immunotherapy. Oncoimmunology. 7(e1389366)2018.PubMed/NCBI View Article : Google Scholar | |
|
Hashimoto K, Nishimura S, Ito T and Akagi M: Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas. Eur J Histochem. 65(3203)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, et al: Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer. 18:1–9. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Guo J, Li YM, Guo H, Hao DP, Xu JX, Huang CC, Han HW, Hou F, Yang SF, Cui JL and Wang HX: Parallel CNN-deep learning clinical-imaging signature for assessing pathologic grade and prognosis of soft tissue sarcoma patients. J Magn Reson Imaging. 61:807–819. 2024.PubMed/NCBI View Article : Google Scholar | |
|
Hashimoto K, Nishimura S, Shinyashiki Y, Ito T, Tanaka H, Ohtani K, Kakinoki R and Akagi M: PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in cutaneous angiosarcoma: A case report. Medicine (Baltimore). 101(e29621)2022.PubMed/NCBI View Article : Google Scholar | |
|
Hashimoto K, Nishimura S, Ito T, Kakinoki R and Akagi M: Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas. Eur J Histochem. 66(3393)2022.PubMed/NCBI View Article : Google Scholar | |
|
D'Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK and Streicher H: Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomized, phase 2 trials. Lancet Oncol. 19:416–426. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yildirim AN, Akyurek M, Okay E, Zenginkinet T, Iyetin Y and Ozkan K: Programmed cell death ligand-1 (PD-L1) expression in desmoid tumors: A retrospective study. Eur Rev Med Pharmacol Sci. 27:5223–5229. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Hashimoto K, Nishimura S, Shinyashiki Y, Ito T, Kakinoki R and Akagi M: Clinicopathological assessment of PD-1-comp/PD-L1 immune checkpoint expression in desmoid tumors. Eur J Histochem. 67(3688)2023.PubMed/NCBI View Article : Google Scholar | |
|
Young RJ, Brown NJ, Reed MW, Hughes D and Woll PJ: Angiosarcoma. Lancet Oncol. 11:983–991. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Ai L, Xu A and Xu J: Roles of PD-1/PD-L1 pathway: Signaling, cancer, and beyond. Adv Exp Med Biol. 1248:33–59. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Lee JB, Ahn BC, Kim SH, Lee YH, Han JW, Jeon MK, Kim SH and Kim HS: Prognostic implications of PD-L1 expression in patients with angiosarcoma. Future Sci OA. 7(FSO691)2021.PubMed/NCBI View Article : Google Scholar | |
|
Shimizu A, Kaira K, Okubo Y, Utsumi D, Yasuda M, Asao T, Nishiyama M, Takahashi K and Ishikawa O: Positive PD-L1 expression predicts worse outcome in cutaneous angiosarcoma. J Glob Oncol. 3:360–369. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Wen W, Zhang Y, Zhang H and Chen Y: Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. J Cancer Res Clin Oncol. 149:969–978. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Tawbi HA, Burgess M, Bolejack V, Van Tine BA, Schuetze SM, Hu J, D'Angelo S, Attia S, Riedel RF, Priebat DA, et al: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 18:1493–1501. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Nowicki TS, Akiyama R, Huang RR, Shintaku IP, Wang X, Tumeh PC, Singh A, Chmielowski B, Denny C, Federman N and Ribas A: Infiltration of CD8 T cells and expression of PD-1 and PD-L1 in synovial sarcoma. Cancer Immunol Res. 5:118–126. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y, Xiong D, Liu Q, Tian Y, Lin H, et al: The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell. 185:4049–4066.e25. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, Meeker AK, Lucia MS, Anders RA, Demarzo AM and Drake CG: Paucity of PD-L1 expression in prostate cancer: Innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 18:325–332. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Chen L and Han X: Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future. J Clin Invest. 125:3384–3391. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al: Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 366:2455–2465. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Italiano A, Bellera C and D'Angelo S: PD1/PD-L1 targeting in advanced soft-tissue sarcomas: A pooled analysis of phase II trials. J Hematol Oncol. 13(55)2020.PubMed/NCBI View Article : Google Scholar | |
|
Somaiah N, Conley AP, Parra ER, Lin H, Amini B, Soto LS, Salazar R, Barreto C, Chen H, Gite S, et al: Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: A single-centre phase 2 trial. Lancet Oncol. 23:1156–1166. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Gordon EM, Chawla SP, Tellez WA, Younesi E, Thomas S, Chua-Alcala VS, Chomoyan H, Valencia C, Brigham DA, Moradkhani A, et al: SAINT: A phase I/Expanded phase II study using safe amounts of ipilimumab, nivolumab and trabectedin as first-line treatment of advanced soft tissue sarcoma. Cancers (Basel). 15(906)2023.PubMed/NCBI View Article : Google Scholar | |
|
Saif A, Verbus EA, Sarvestani AL, Teke ME, Lambdin J, Hernandez JM and Kirsch DG: A randomized trial of pembrolizumab & radiotherapy versus radiotherapy in high-risk soft tissue sarcoma of the extremity (SU2C-SARC032). Ann Surg Oncol. 30:683–685. 2023.PubMed/NCBI View Article : Google Scholar | |
|
Liao Z, Teng J, Li T, Liu H, Li T, Zhang C, Xing R, Teng S, Yang Y, Zhao J, et al: Evaluation of the efficacy and safety of immunotherapy in sarcoma: A two-center study. Front Immunol. 15(1292325)2024.PubMed/NCBI View Article : Google Scholar | |
|
Babatunde O, Rosenbaum E, Kelly CM, Desir-Camille R, Keohan ML, Banks L, Avutu V, Chan J, Reed D, Gounder M, et al: 1752P A retrospective single-center study of outcomes to immune checkpoint blockade-based therapy in leiomyosarcoma. Ann Oncol. 35(S1045)2024. | |
|
Sonpavde GP, Grivas P, Lin Y, Hennessy D and Hunt JD: Immune-related adverse events with PD-1 versus PD-L1 inhibitors: A meta-analysis of 8730 patients from clinical trials. Future Oncol. 17:2545–2558. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L and Korenstein D: Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: Systematic review and meta-analysis. BMJ. 360(k793)2018.PubMed/NCBI View Article : Google Scholar | |
|
Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M, Xu Y, Zhao J, Zhong W and Wang M: Risk factors for immune-related adverse events: What have we learned and what lies ahead? Biomark Res. 9(79)2021.PubMed/NCBI View Article : Google Scholar | |
|
Kalinich M, Murphy W, Wongvibulsin S, Pahalyants V, Yu KH, Lu C, Wang F, Zubiri L, Naranbhai V, Gusev A, et al: Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: Study of a population level insurance claims database from the USA. J Immunother Cancer. 9(e001935)2021.PubMed/NCBI View Article : Google Scholar | |
|
Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau J, et al: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 39:4073–4126. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Postow MA, Sidlow R and Hellmann MD: Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 378:158–168. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol. 4:1721–1728. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Yi M, Zheng X, Niu M, Zhu S, Ge H and Wu K: Combination strategies with PD-1/PD-L1 blockade: Current advances and future directions. Mol Cancer. 21(28)2022.PubMed/NCBI View Article : Google Scholar | |
|
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lynch MM, Alexiev BA, Schroeder BA and Pollack SM: Combinations of chemotherapy and PD-1/PD-L1 inhibitors in sarcoma. Curr Treat Options Oncol. 23:1861–1876. 2022.PubMed/NCBI View Article : Google Scholar | |
|
Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Steward R, et al: Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 74:5458–5468. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Patel KR, Martinez A, Stahl JM, Logan SJ, Perricone AJ, Ferris MJ, Buchwald ZS, Chowdhary M, Delman KA, Monson DK, et al: Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. Oncoimmunology. 7(e1442168)2018.PubMed/NCBI View Article : Google Scholar | |
|
Katsuki S, Takahashi Y, Tamari K, Minami K, Takenaka W, Ibuki Y, Yamamoto J, Tatekawa S, Hayashi K, Seo Y, et al: Radiation therapy enhances systemic antitumor efficacy in PD-L1 therapy regardless of sequence of radiation in murine osteosarcoma. PLoS One. 17(e0271205)2022.PubMed/NCBI View Article : Google Scholar | |
|
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NJ, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 369:122–133. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Huang S, Zheng G and Yang K: Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: A systematic review and meta-analysis. World J Surg Oncol. 21(349)2023.PubMed/NCBI View Article : Google Scholar | |
|
Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, Chenoweth A, Chauhan J, Bax HJ, McCraw A, et al: Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: treatment of melanoma and immune mechanisms of action. Eur J Immunol. 51:544–556. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Roussot N, Fumet JD, Limagne E, Thibaudin M, Hervieu A, Hennequin A, Zanetta S, Dalens L, Fourrier T, Galland L, et al: A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer. BMC Cancer. 23(1080)2023.PubMed/NCBI View Article : Google Scholar | |
|
Huang D, Ke L, Cui H and Li S: Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: A systematic review and meta-analysis of randomized controlled trials. BMC Cancer. 23(474)2023.PubMed/NCBI View Article : Google Scholar | |
|
Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, et al: Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer. J Clin Oncol. 42:1241–1251. 2024.PubMed/NCBI View Article : Google Scholar |
